A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection
The Journal of Infectious Diseases · 11.01.2023 · 227 (2) · 226-235
DOI: 10.1093/infdis/jiac362 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 03.09.2022. Verfasst von Fadi Shehadeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Thymosin, COVID-19, Lymphopenia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: SciClone Pharmaceuticals International Ltd.
Abstract (Originalsprache)
Background
Thymosin-α-1 (Tα1) may be a treatment option for coronavirus disease 2019 (COVID-19), but efficacy and safety data remain limited.
Methods
Prospective, open-label, randomized trial assessing preliminary efficacy and safety of thymalfasin (synthetic form of Tα1), compared with the standard of care, among hospitalized patients with hypoxemia and lymphocytopenia due to COVID-19.
Results
A total of 49 patients were included in this analysis. Compared with control patients, the incidence of clinical recovery was higher for treated patients with either baseline low-flow oxygen (subdistribution hazard ratio, 1.48 [95% confidence interval, .68–3.25]) or baseline high-flow oxygen (1.28 [.35–4.63]), although neither difference was significant. Among patients with baseline low-flow oxygen, treated patients, compared with control patients, had an average difference of 3.84 times more CD4+ T cells on day 5 than on day 1 (P = .01). Nine serious adverse events among treated patients were deemed not related to Tα1.
Conclusions
Tα1 increases CD4+ T-cell count among patients with baseline low-flow oxygen support faster than the standard of care and may have a role in the management of hospitalized patients with hypoxemia and lymphocytopenia due to COVID-19. Clinical Trials Registration NCT04487444.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
- School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece.
Förderung
- SciClone Pharmaceuticals International Ltd
Zitieren
APA
Shehadeh, F., Benitez, G., Mylona, E. K., Tran, Q. L., Tsikala-Vafea, M., Atalla, E., Kaczynski, M., & Mylonakis, E. (2023). A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. The Journal of Infectious Diseases, 227(2), 226-235. https://doi.org/10.1093/infdis/jiac362
Vancouver
Shehadeh F, Benitez G, Mylona EK, Tran QL, Tsikala-Vafea M, Atalla E, et al. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. The Journal of Infectious Diseases. 2023;227(2):226-235. doi:10.1093/infdis/jiac362
BibTeX
@article{Shehadeh2023,
author = {Shehadeh, Fadi and Benitez, Gregorio and Mylona, Evangelia K and Tran, Quynh-Lam and Tsikala-Vafea, Maria and Atalla, Eleftheria and Kaczynski, Matthew and Mylonakis, Eleftherios},
title = {A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection},
journal = {The Journal of Infectious Diseases},
year = {2023},
volume = {227},
number = {2},
pages = {226--235},
doi = {10.1093/infdis/jiac362}
}
EUVIMED